ArticleAnnals of clinical and translational neurology2022
Factors predicting neuronal surface antibodies in the elderly with new-onset and unknown seizures.
Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Association of central adiposity indices with cognitive impairment in elderly populations: Development and validation of a risk prediction nomogram using NHANES and CHARLS cohorts.Journal of Alzheimer's disease : JAD · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate risk factors of neuronal surface antibodies (NSAbs) and develop a nomogram that could identify patients at the odds of NSAbs among the elderly (aged 60 years or older) with new-onset seizures of unknown etiology.
methodsClinical data for aged ≥60 years diagnosed with new-onset seizures of unknown etiology were retrospectively reviewed. A nomogram based on multivariable logistic regression was constructed. Model performance of nomogram was evaluated using area under the curve (AUC), calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC). Meanwhile, it was internally validated by bootstrap validation in current cohort.
resultsOf 147 patients included in final analysis, 68 (46.3%) had NSAbs-mediated encephalitis. Six factors were identified: duration of seizures less than 3 months (OR:14.259; 95% CI: 4.480-45.386), focal-onset seizures (OR:12.457; 95% CI: 2.710-57.261), psychiatric deficits (OR:10.063; 95% CI: 3.231-31.343), sleep disorders (OR:3.091; 95% CI: 1.011-9.454), hyponatremia (OR:6.252; 95% CI: 1.445-27.043), and medial temporal lobe (MTL) lesions on MRI (OR:4.102; 95% CI: 1.382-12.169). The nomogram had a good discrimination with an AUC of 0.916 and with a corrected AUC of 0.881 after the bootstrapping validation, our model also exhibited a better predictive performance than scoring systems commonly used clinically. Additionally, the calibration curve showed that predicted NSAbs-positive rates of nomogram were closely aligned with actual observed results. Moreover, the nomogram achieved well on clinical utility by using the DCA and CIC.
interpretationOur nomogram may provide a convenient and useful tool for identifying the elderly with new-onset seizures of unknown etiology who are at risk of NSAbs-mediated encephalitis, which would allow these patients receive earlier immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.